Global CAR T-Cell Immunotherapy Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • CAR T-Cell Immunotherapy market report explains the definition, types, applications, major countries, and major players of the CAR T-Cell Immunotherapy market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Pfizer

    • Celgene

    • Kite Pharma

    • Novartis

    • Ziopharm Oncology

    • Adaptimmune

    • Cellectis

    • Minerva Biotechnologies

    • Aurora Biopharma

    • Gilead

    • Mustang Bio

    • Bellicum

    • Creative Biolabs

    • AbbVie

    • Oxford BioMedica

    • CARsgen Therapeutics

    • Xyphos

    By Type:

    • Monotherapy

    • Combination Therapy

    By End-User:

    • Hematologic Malignancies

    • Solid Malignancies

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global CAR T-Cell Immunotherapy Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 CAR T-Cell Immunotherapy Outlook to 2028- Original Forecasts

    • 2.2 CAR T-Cell Immunotherapy Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term CAR T-Cell Immunotherapy Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global CAR T-Cell Immunotherapy Market- Recent Developments

    • 6.1 CAR T-Cell Immunotherapy Market News and Developments

    • 6.2 CAR T-Cell Immunotherapy Market Deals Landscape

    7 CAR T-Cell Immunotherapy Raw Materials and Cost Structure Analysis

    • 7.1 CAR T-Cell Immunotherapy Key Raw Materials

    • 7.2 CAR T-Cell Immunotherapy Price Trend of Key Raw Materials

    • 7.3 CAR T-Cell Immunotherapy Key Suppliers of Raw Materials

    • 7.4 CAR T-Cell Immunotherapy Market Concentration Rate of Raw Materials

    • 7.5 CAR T-Cell Immunotherapy Cost Structure Analysis

      • 7.5.1 CAR T-Cell Immunotherapy Raw Materials Analysis

      • 7.5.2 CAR T-Cell Immunotherapy Labor Cost Analysis

      • 7.5.3 CAR T-Cell Immunotherapy Manufacturing Expenses Analysis

    8 Global CAR T-Cell Immunotherapy Import and Export Analysis (Top 10 Countries)

    • 8.1 Global CAR T-Cell Immunotherapy Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global CAR T-Cell Immunotherapy Export by Region (Top 10 Countries) (2017-2028)

    9 Global CAR T-Cell Immunotherapy Market Outlook by Types and Applications to 2022

    • 9.1 Global CAR T-Cell Immunotherapy Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Monotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Combination Therapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global CAR T-Cell Immunotherapy Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hematologic Malignancies Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Solid Malignancies Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise CAR T-Cell Immunotherapy Market Analysis and Outlook till 2022

    • 10.1 Global CAR T-Cell Immunotherapy Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.2.2 Canada CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.2.3 Mexico CAR T-Cell Immunotherapy Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.2 UK CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.3 Spain CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.4 Belgium CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.5 France CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.6 Italy CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.7 Denmark CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.8 Finland CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.9 Norway CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.10 Sweden CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.11 Poland CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.12 Russia CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.3.13 Turkey CAR T-Cell Immunotherapy Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.2 Japan CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.3 India CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.4 South Korea CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.5 Pakistan CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.6 Bangladesh CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.7 Indonesia CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.8 Thailand CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.9 Singapore CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.10 Malaysia CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.11 Philippines CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.4.12 Vietnam CAR T-Cell Immunotherapy Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.5.2 Colombia CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.5.3 Chile CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.5.4 Argentina CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.5.5 Venezuela CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.5.6 Peru CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.5.7 Puerto Rico CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.5.8 Ecuador CAR T-Cell Immunotherapy Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.6.2 Kuwait CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.6.3 Oman CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.6.4 Qatar CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.6.5 Saudi Arabia CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.6.6 United Arab Emirates CAR T-Cell Immunotherapy Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.7.2 South Africa CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.7.3 Egypt CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.7.4 Algeria CAR T-Cell Immunotherapy Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia CAR T-Cell Immunotherapy Consumption (2017-2022)

      • 10.8.2 New Zealand CAR T-Cell Immunotherapy Consumption (2017-2022)

    11 Global CAR T-Cell Immunotherapy Competitive Analysis

    • 11.1 Pfizer

      • 11.1.1 Pfizer Company Details

      • 11.1.2 Pfizer CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Pfizer CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.1.4 Pfizer CAR T-Cell Immunotherapy Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Celgene

      • 11.2.1 Celgene Company Details

      • 11.2.2 Celgene CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Celgene CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.2.4 Celgene CAR T-Cell Immunotherapy Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Kite Pharma

      • 11.3.1 Kite Pharma Company Details

      • 11.3.2 Kite Pharma CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Kite Pharma CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.3.4 Kite Pharma CAR T-Cell Immunotherapy Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Novartis

      • 11.4.1 Novartis Company Details

      • 11.4.2 Novartis CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Novartis CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.4.4 Novartis CAR T-Cell Immunotherapy Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Ziopharm Oncology

      • 11.5.1 Ziopharm Oncology Company Details

      • 11.5.2 Ziopharm Oncology CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Ziopharm Oncology CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.5.4 Ziopharm Oncology CAR T-Cell Immunotherapy Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Adaptimmune

      • 11.6.1 Adaptimmune Company Details

      • 11.6.2 Adaptimmune CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Adaptimmune CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.6.4 Adaptimmune CAR T-Cell Immunotherapy Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Cellectis

      • 11.7.1 Cellectis Company Details

      • 11.7.2 Cellectis CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Cellectis CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.7.4 Cellectis CAR T-Cell Immunotherapy Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Minerva Biotechnologies

      • 11.8.1 Minerva Biotechnologies Company Details

      • 11.8.2 Minerva Biotechnologies CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Minerva Biotechnologies CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.8.4 Minerva Biotechnologies CAR T-Cell Immunotherapy Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Aurora Biopharma

      • 11.9.1 Aurora Biopharma Company Details

      • 11.9.2 Aurora Biopharma CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Aurora Biopharma CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.9.4 Aurora Biopharma CAR T-Cell Immunotherapy Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Gilead

      • 11.10.1 Gilead Company Details

      • 11.10.2 Gilead CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Gilead CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.10.4 Gilead CAR T-Cell Immunotherapy Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Mustang Bio

      • 11.11.1 Mustang Bio Company Details

      • 11.11.2 Mustang Bio CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Mustang Bio CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.11.4 Mustang Bio CAR T-Cell Immunotherapy Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    • 11.12 Bellicum

      • 11.12.1 Bellicum Company Details

      • 11.12.2 Bellicum CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.12.3 Bellicum CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.12.4 Bellicum CAR T-Cell Immunotherapy Product Portfolio

      • 11.12.5 Recent Research and Development Strategies

    • 11.13 Creative Biolabs

      • 11.13.1 Creative Biolabs Company Details

      • 11.13.2 Creative Biolabs CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.13.3 Creative Biolabs CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.13.4 Creative Biolabs CAR T-Cell Immunotherapy Product Portfolio

      • 11.13.5 Recent Research and Development Strategies

    • 11.14 AbbVie

      • 11.14.1 AbbVie Company Details

      • 11.14.2 AbbVie CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.14.3 AbbVie CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.14.4 AbbVie CAR T-Cell Immunotherapy Product Portfolio

      • 11.14.5 Recent Research and Development Strategies

    • 11.15 Oxford BioMedica

      • 11.15.1 Oxford BioMedica Company Details

      • 11.15.2 Oxford BioMedica CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.15.3 Oxford BioMedica CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.15.4 Oxford BioMedica CAR T-Cell Immunotherapy Product Portfolio

      • 11.15.5 Recent Research and Development Strategies

    • 11.16 CARsgen Therapeutics

      • 11.16.1 CARsgen Therapeutics Company Details

      • 11.16.2 CARsgen Therapeutics CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.16.3 CARsgen Therapeutics CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.16.4 CARsgen Therapeutics CAR T-Cell Immunotherapy Product Portfolio

      • 11.16.5 Recent Research and Development Strategies

    • 11.17 Xyphos

      • 11.17.1 Xyphos Company Details

      • 11.17.2 Xyphos CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 11.17.3 Xyphos CAR T-Cell Immunotherapy Main Business and Markets Served

      • 11.17.4 Xyphos CAR T-Cell Immunotherapy Product Portfolio

      • 11.17.5 Recent Research and Development Strategies

    12 Global CAR T-Cell Immunotherapy Market Outlook by Types and Applications to 2028

    • 12.1 Global CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Monotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Combination Therapy Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hematologic Malignancies Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Solid Malignancies Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise CAR T-Cell Immunotherapy Market Analysis and Outlook to 2028

    • 13.1 Global CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.2.2 Canada CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.2.3 Mexico CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.2 UK CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.3 Spain CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.4 Belgium CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.5 France CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.6 Italy CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.7 Denmark CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.8 Finland CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.9 Norway CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.10 Sweden CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.11 Poland CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.12 Russia CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.3.13 Turkey CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.2 Japan CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.3 India CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.4 South Korea CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.8 Thailand CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.9 Singapore CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.11 Philippines CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.5.2 Colombia CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.5.3 Chile CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.5.4 Argentina CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.5.6 Peru CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.6.3 Oman CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.6.4 Qatar CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.7.2 South Africa CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.7.3 Egypt CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.7.4 Algeria CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand CAR T-Cell Immunotherapy Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of CAR T-Cell Immunotherapy

    • Figure of CAR T-Cell Immunotherapy Picture

    • Table Global CAR T-Cell Immunotherapy Import by Region (Top 10 Countries) (2017-2028)

    • Table Global CAR T-Cell Immunotherapy Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Monotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Combination Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Hematologic Malignancies Consumption and Growth Rate (2017-2022)

    • Figure Global Solid Malignancies Consumption and Growth Rate (2017-2022)

    • Figure Global CAR T-Cell Immunotherapy Consumption by Country (2017-2022)

    • Table North America CAR T-Cell Immunotherapy Consumption by Country (2017-2022)

    • Figure United States CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Canada CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Mexico CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Table Europe CAR T-Cell Immunotherapy Consumption by Country (2017-2022)

    • Figure Germany CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure UK CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Spain CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Belgium CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure France CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Italy CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Denmark CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Finland CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Norway CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Sweden CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Poland CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Russia CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Turkey CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Table APAC CAR T-Cell Immunotherapy Consumption by Country (2017-2022)

    • Figure China CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Japan CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure India CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure South Korea CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Pakistan CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Indonesia CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Thailand CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Singapore CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Malaysia CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Philippines CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Vietnam CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Table South America CAR T-Cell Immunotherapy Consumption by Country (2017-2022)

    • Figure Brazil CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Colombia CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Chile CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Argentina CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Venezuela CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Peru CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Ecuador CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Table GCC CAR T-Cell Immunotherapy Consumption by Country (2017-2022)

    • Figure Bahrain CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Kuwait CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Oman CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Qatar CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Table Africa CAR T-Cell Immunotherapy Consumption by Country (2017-2022)

    • Figure Nigeria CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure South Africa CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Egypt CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Algeria CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Table Oceania CAR T-Cell Immunotherapy Consumption by Country (2017-2022)

    • Figure Australia CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure New Zealand CAR T-Cell Immunotherapy Consumption and Growth Rate (2017-2022)

    • Table Pfizer Company Details

    • Table Pfizer CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Pfizer CAR T-Cell Immunotherapy Product Portfolio

    • Table Celgene Company Details

    • Table Celgene CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgene CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Celgene CAR T-Cell Immunotherapy Product Portfolio

    • Table Kite Pharma Company Details

    • Table Kite Pharma CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kite Pharma CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Kite Pharma CAR T-Cell Immunotherapy Product Portfolio

    • Table Novartis Company Details

    • Table Novartis CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Novartis CAR T-Cell Immunotherapy Product Portfolio

    • Table Ziopharm Oncology Company Details

    • Table Ziopharm Oncology CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ziopharm Oncology CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Ziopharm Oncology CAR T-Cell Immunotherapy Product Portfolio

    • Table Adaptimmune Company Details

    • Table Adaptimmune CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Adaptimmune CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Adaptimmune CAR T-Cell Immunotherapy Product Portfolio

    • Table Cellectis Company Details

    • Table Cellectis CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cellectis CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Cellectis CAR T-Cell Immunotherapy Product Portfolio

    • Table Minerva Biotechnologies Company Details

    • Table Minerva Biotechnologies CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Minerva Biotechnologies CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Minerva Biotechnologies CAR T-Cell Immunotherapy Product Portfolio

    • Table Aurora Biopharma Company Details

    • Table Aurora Biopharma CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Aurora Biopharma CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Aurora Biopharma CAR T-Cell Immunotherapy Product Portfolio

    • Table Gilead Company Details

    • Table Gilead CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Gilead CAR T-Cell Immunotherapy Product Portfolio

    • Table Mustang Bio Company Details

    • Table Mustang Bio CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mustang Bio CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Mustang Bio CAR T-Cell Immunotherapy Product Portfolio

    • Table Bellicum Company Details

    • Table Bellicum CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bellicum CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Bellicum CAR T-Cell Immunotherapy Product Portfolio

    • Table Creative Biolabs Company Details

    • Table Creative Biolabs CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Creative Biolabs CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Creative Biolabs CAR T-Cell Immunotherapy Product Portfolio

    • Table AbbVie Company Details

    • Table AbbVie CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table AbbVie CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table AbbVie CAR T-Cell Immunotherapy Product Portfolio

    • Table Oxford BioMedica Company Details

    • Table Oxford BioMedica CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Oxford BioMedica CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Oxford BioMedica CAR T-Cell Immunotherapy Product Portfolio

    • Table CARsgen Therapeutics Company Details

    • Table CARsgen Therapeutics CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table CARsgen Therapeutics CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table CARsgen Therapeutics CAR T-Cell Immunotherapy Product Portfolio

    • Table Xyphos Company Details

    • Table Xyphos CAR T-Cell Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Xyphos CAR T-Cell Immunotherapy Main Business and Markets Served

    • Table Xyphos CAR T-Cell Immunotherapy Product Portfolio

    • Figure Global Monotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Combination Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hematologic Malignancies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Solid Malignancies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CAR T-Cell Immunotherapy Consumption Forecast by Country (2022-2028)

    • Table North America CAR T-Cell Immunotherapy Consumption Forecast by Country (2022-2028)

    • Figure United States CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe CAR T-Cell Immunotherapy Consumption Forecast by Country (2022-2028)

    • Figure Germany CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure France CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC CAR T-Cell Immunotherapy Consumption Forecast by Country (2022-2028)

    • Figure China CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure India CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Table South America CAR T-Cell Immunotherapy Consumption Forecast by Country (2022-2028)

    • Figure Brazil CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC CAR T-Cell Immunotherapy Consumption Forecast by Country (2022-2028)

    • Figure Bahrain CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa CAR T-Cell Immunotherapy Consumption Forecast by Country (2022-2028)

    • Figure Nigeria CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania CAR T-Cell Immunotherapy Consumption Forecast by Country (2022-2028)

    • Figure Australia CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand CAR T-Cell Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.